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Dialysis patients: vulnerable
group of patients
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To the Editor: We have read the article by Anderson et al,1
as well as the editorial by Abdel-Kader and Lynn Unruh2
with great interest and would like to comment.
It is clear from the article by Anderson et al. and the
editorial that dialysis patients belong to an extremely
vulnerable group and that they should get very special
attention and care in case of natural disasters.
Our world is not perfect and even today there are wars
throughout our planet. These situations are especially
threatening for dialysis patients and those with renal
transplants.
Unfortunately, Croatian nephrologists had this kind of
experience 18 years ago.3
There were 31 dialysis units in Croatia in 27 cities
providing care for 1819 patients during 1991. When the war
started, eight dialysis units with 402 patients had to be
evacuated; among them two centers were completely
destroyed. Most patients were evacuated without any
medical records and a majority of them arrived in Zagreb,
the capital of Croatia. As the war escalated, some of the
patients were transferred to smaller towns, far from the
frontline. In spite of many problems, all patients were treated
properly and most of them did not miss the dialysis sessions.
This was achieved thanks to the immense efforts of the
medical staff and humanitarian aid from all over the word.
Dialysis patients are definitely a very vulnerable and
imperiled group, and it is necessary to plan how to take
care of them in special circumstances, not just during natural
disasters but also in case of unfortunate and tragic wars.
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HIV-1 entry into human podocytes
is mediated through lipid rafts
Kidney International (2010) 77, 72–73; doi:10.1038/ki.2009.366
To the Editor: We read with the interest the article by Khan
et al.1 Lipid rafts have been reported to have an important
role for human immunodeficiency virus (HIV)-1 entry into
several cells.2,3 Renal biopsy studies have demonstrated that
HIV-1 infection of renal epithelial cells contribute to the
pathogenesis of HIV-1-associated nephropathy.4,5 As renal
epithelial cells do not express classical HIV-1 receptors, their
entry into podocytes remains a mystery.6 We studied the role
l e t te r to the ed i to r http://www.kidney-international.org
& 2010 International Society of Nephrology
LTR RU5
Mock
Tubulin
Control MβCD
*
R
el
at
iv
e 
LT
R
 R
U5
c.
p.
m
. u
ni
ts
6
4
2
0
LTR RU5
Mock Control
HIV-1660
MβCD MβCD/cholesterol
α-Tubulin
*
H
IV
-1
 e
nt
ry
 in
hi
bi
tio
n 
(%
) 100%
80%
60%
40%
20%
0%
Control/PBS MβCD
X4 HIV-1R5 HIV-1
72 Kidney International (2010) 77, 72–75
of lipid rafts in the entry of HIV-1 into podocytes.
Conditionally immortalized human podocytes were exposed
to primary strains of HIV-1 with different co-receptor
usage—R5 HIV-192US660 and X4 HIV-192HT599. As shown in
Figure 1a, human podocytes exposed to either R5 or X4 viral
strains were positive for HIV-1-specific strong-stop DNA
(LTR RU5).
To determine the role of lipid rafts, we evaluated the effect
of methyl-b-cyclodextrin (MbCD) on podocyte HIV-1 entry.
MbCD is a derivative of cyclic oligosaccharides and has a
lipophilic property that extracts cholesterol from membranes,
resulting in lipid rafts disruption.7 To test the drug effect of
MbCD on mock-infected podocytes, we used the cholera
toxin B-subunit, a specific marker for the lipid rafts
associated GSL GM1.8 MbCD treatment decreased approxi-
mately 70% podocyte cholesterol expression (Figure 1b).
As shown in Figure 1c, podocyte viral accumulation
significantly decreased after MbCD treatment when compared
with the mock-treated control. As cholesterol-replenished
cells (first exposed to cyclodextrin and then replenis-
hed with exogenous water-soluble cholesterol) showed
comparable levels of viral entry (as observed in untreated
cells), it appeared that the inhibition of HIV-1 entry was not
due to the potential toxicity of MbCD (Figure 1d). Inhibi-
tion of viral entry after cholesterol extraction was indepen-
dent of viral tropism (data not shown). These results support
the notion that cholesterol (maintenance of lipid raft
integrity) is required for entry of both X4 and R5 HIV-1.
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The study by Mikulak and Singhal1 showing the impor-
tance of cholesterol in the HIV infection of a human renal
podocyte model system provides additional support for the
important role of cell membrane ‘lipid rafts’ in HIV
infection. Our studies on the binding of R5 gp120 within
the human nephron showed that binding was restricted
to tubular epithelial cells. gp120–tubular cell binding
could be eliminated by detergent extraction of the sections,
suggesting that binding occurred within the non-DRM (‘non-
raft’) fraction. Although podocytes were not specifically
identified in our study, the lack of gp120 glomerular binding
we found indicates that gp120-mediated HIV–podocyte
binding must be significantly less than to renal tubular
epithelial cells.2 The lipid raft requirement for HIV infection
has been contested,3,4 and it may be that the lipid raft
requirement varies between HIV target cell types. In addition,
our studies indicate that Gb3 is a resistance factor against HIV
infection5 rather than a mediator of infection. Thus, there is a
Figure 1 |Role of lipid rafts in podocyte HIV-entry. (a) Podocytes were exposed to different primary human immunodeficiency virus
(HIV)-1 strains: R5 HIV-192US660 and HIV-192HT599. Cells were pulsed with the virus for 24 h followed by washing with phosphate-buffered
saline (PBS), and then treatment with 0.05% trypsin at 37 1C for 10min (to eliminate non-internalized virus). The cells were washed again
four times with PBS and then plated for culture. After 24 h, cells were trypsinized again, washed, lysed, and analyzed for HIV-specific LTR RU5
by PCR. One representative experiment out of three is shown. Mock infection served as a negative control. (b) Equal numbers of podocytes
were incubated in serum-free media (SFM) containing either buffer or methyl-b-cyclodextrin (MbCD, 10mM) for 30min. At the end of the
incubation period, cells were washed and stained with Alexa Fluor 555–conjugated cholera toxin B-subunit (CTx-B) and DAPI. Subsequently,
cells were studied under Zeiss Axiovert (Carl Zeiss, Oberkochen, Germany) 200M with 40 numerical aperture. The presence of podocyte
lipid raft ganglioside GM1 is indicated by red fluorescence, whereas blue fluorescence represents nuclei (DAPI). (c) Podocytes were
pre-incubated in SFM containing either buffer (Control) or MbCD (10mM) for 30min. Subsequently, cells were washed and pulsed with
HIV-192US660 (pre-treated with 200U/ml of RNase-free DNase) for 2 h in SFM. After HIV-1 pulsing, cells were trypsinized, washed, and analyzed
for HIV-1-specific LTR RU5 by PCR. The percent of inhibition represents the percent of the ratio of the relative LTR RU5 c.p.m. units between
samples treated with MbCD and PBS/Control (means±s.d., n¼ 3). (d) After MbCD, treatment podocytes were reconstituted with water-
soluble cholesterol (400 mg/ml) for 2 h, washed, and subsequently incubated in SFM containing HIV-192US660 for 2 h. After HIV-1 pulsing, cells
were trypsinized, washed and analyzed for HIV-1-specific LTR RU5 by PCR. One representative experiment out of three is shown for the
presence of HIV-1-specific strong-stop DNA. Amplification of the a-tubulin gene was used to control for the amount of DNA. The data
represent the means±s.d. of three independent experiments. Mock served as a negative control. *Po0.0001 compared with control.
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